We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Snibe Diagnostic’s Maglumi SARS-CoV-2 Neutralizing Antibody Assay Receives CE Mark

By LabMedica International staff writers
Posted on 12 Jan 2021
Illustration
Illustration
Snibe Diagnostic (Shenzhen, China) has received CE marking for its Maglumi SARS-CoV-2 Neutralizing Antibody Assay.

The fully automated test can detect neutralizing antibodies against SARS-CoV-2 within 20 minutes when used with the company’s Maglumi analyzers. Designed for highly sensitive and specific detection of SARS-CoV-2 neutralizing antibodies, the assay aims to address the urgent need for assessing immunity during the COVID-19 pandemic. It can be used to determine the immune status of COVID-19 patients and individuals who have been vaccinated against the virus. By evaluating immunity in individuals and the community, the test can provide “immunity certification” for those returning to the society.

The new assay shows a high agreement rate with the gold standard Virus Neutralization Test (VNT/PRNT), indicating that it could be a useful tool for assessment of the immunity to SARS-CoV-2 infection. The Maglumi SARS-CoV-2 Neutralizing Antibody Assay could also serve as an important tool for assessment of the efficacy of COVID-19 vaccines.

Related Links:
Snibe Diagnostic

Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Online QC Software
Acusera 24•7
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Pipette Calibration System
Artel PCS®

Channels

Molecular Diagnostics

view channel
Image: New findings indicate that chimeric RNAs, once viewed as cancer byproducts, can also be part of normal physiology with regulatory functions (Image credit: Adobe Stock)

Female-Specific RNA Biomarker May Help Explain Sex Differences in Immune Disease

Women show distinct susceptibility to infectious diseases and higher rates of autoimmune disorders, yet the molecular drivers remain unclear. This gap has limited sex-specific diagnostic and prognostic tools.... Read more

Microbiology

view channel
Image: Multidrug-resistant Klebsiella pneumoniae is a growing community health concern, causing recurrent UTIs in older adults and complicating first-line antibiotic treatment (Image Credit: Adobe Stock)

Study Reveals Widespread Community Spread of Drug-Resistant Klebsiella

Multidrug-resistant Klebsiella pneumoniae is an escalating community health concern, driving recurrent urinary tract infections in older adults and complicating first-line antibiotic therapy.... Read more

Industry

view channel
Image: Volition’s Nu.Q NETs test detects markers associated with neutrophil extracellular traps, which are released during NETosis and linked to sepsis and other acute and chronic disorders (Image credit: iStock)

Collaboration Aims to Broaden Access to NETosis-Linked Disease Testing

VolitionRx Limited (Henderson, NV, USA), a multinational epigenetics company, has announced a collaboration with Sysmex Corporation (Kobe, Japan), a global leader in in vitro diagnostics, to optimize Volition’s Nu.... Read more
ADLM